# CJC-1295 vs Sermorelin: Side-by-Side Comparison — AJW Peptides

> A direct side-by-side comparison of CJC-1295 and sermorelin — two GHRH-analog research peptides — across peptide class, half-life, evidence base, regulatory and WADA status, and key cautions.

Same receptor, same downstream axis — but different half-lives, different evidence bases, and a very different regulatory picture. Here is what the literature actually says about each.

## The short version

Both [CJC-1295](/cjc-1295) and [sermorelin](/sermorelin) act on the same receptor — the GHRH receptor on the anterior pituitary — and both stimulate the body's own GH in its natural pulsatile pattern. Their pharmacological logic is shared. What separates them is duration, engineering, clinical history, and regulatory standing. Sermorelin is the natural 1-29 fragment of GHRH, short-lived, once formally FDA-approved for pediatric GH deficiency, and now a 503A Category 1 compounded substance with a real clinical trial record. CJC-1295 is an engineered multi-day analog with impressive but narrow human PK data, a discontinued development program, and no pathway to approved use [1][4][10][11]. Neither is a supplement. Neither has been proven to benefit healthy adults for anti-aging or performance purposes. This table makes the specifics direct.

## The comparison matrix

| Dimension | CJC-1295 | Sermorelin |
| --- | --- | --- |
| Peptide class | Tetrasubstituted hGRF(1-29) analog; DAC variant covalently binds serum albumin | Natural GHRH fragment — 29 aa N-terminal sequence; no protease-resistance substitutions |
| Mechanism | GHRH-R agonist; pulsatile GH release preserved; DAC form sustains action via albumin binding | GHRH-R agonist; minimal-active-fragment; physiologic feedback (somatostatin / IGF-1) fully intact |
| Half-life | DAC form: 5.8-8.1 days [4]; no-DAC form: hours | Minutes to low hours; cleared rapidly |
| Most-studied in | Healthy adult PK (GH/IGF-1 elevation); GHRH-knockout mouse growth normalization | GH-deficient children (growth velocity); older adult cognition (GHRH analog class) |
| Human evidence | Early PK studies (healthy adults, n=small); no efficacy trials; no long-term safety data [4][5] | Multicenter pediatric trial (approved indication) [11]; adult GHRH-analog RCT [8]; editorial synthesis [9][10] |
| FDA status | Never approved; not recommended for 503A compounding bulks list (PCAC Oct 2024) [1] | Previously approved (pediatric GH deficiency); commercially withdrawn 2008; Category 1 503A compounded substance [10] |
| WADA status | Prohibited at all times — Section S2 (Peptide Hormones, Growth Factors, Related Substances) [2] | Prohibited in sport; GHRH analogs banned under hormone and metabolic modulators |
| Key caution | Immunogenicity flagged by FDA; sustained IGF-1 elevation; discontinued Phase 2 program; DAC/no-DAC routinely confused [1][4][7] | Anti-aging benefit not proven; long-term healthy-adult data lacking; continuous dosing can blunt GH response [9][11] |

## Half-life: the central difference

The defining difference between these two compounds is not the mechanism — it is how long they stay active. Sermorelin is cleared in minutes to low hours. A single dose fires a GH pulse and is gone. CJC-1295 DAC, by contrast, covalently bonds to serum albumin and stays biologically active for roughly 5-8 days, raising GH and IGF-1 continuously during that window [4]. That sustained elevation is both the pharmacological point and the origin of most of its safety concerns: fluid retention, glucose-sparing effects, and prolonged IGF-1 exposure all intensify with duration. The no-DAC form of CJC-1295 (Modified GRF 1-29) has a half-life of hours rather than days — closer to sermorelin — but is frequently mislabeled or confused with the DAC form in community and commercial contexts [7].

## Evidence and regulatory history

These two compounds have genuinely different relationships with regulators and clinical data.

Sermorelin earned an FDA approval through the standard NDA pathway for pediatric GH deficiency and was studied in a multicenter clinical trial showing accelerated growth velocity [11]. The 2008 commercial withdrawal was a business decision, not a regulatory action. FDA now treats sermorelin as a Category 1 bulk drug substance under the 503A compounding policy — meaning it can be compounded by licensed pharmacies without FDA initiating enforcement action. The editorial case for sermorelin as a more physiologic secretagogue than recombinant GH comes from a real mechanistic argument [10].

CJC-1295's path is the opposite. Its development program was discontinued before reaching approval. At the October 2024 FDA Pharmacy Compounding Advisory Committee, the FDA reviewed GH secretagogues and did not recommend CJC-1295 for the 503A compounding bulks list, citing immunogenicity among other concerns [1]. The human evidence that exists — genuinely solid PK data showing sustained GH/IGF-1 elevation [4][5] — was generated for pharmacology characterization, not for an approved indication. There is no large or long-term safety trial.

For practical purposes: sermorelin has more regulatory legitimacy and more clinical data. CJC-1295 has more potent and prolonged pharmacodynamics and a more uncertain safety picture.

## What neither of them is

Both compounds stimulate GH release. Neither is exogenous GH. Neither has been shown in rigorous controlled trials to benefit healthy adults for anti-aging, muscle building, or fat loss at the population level. A 2008 *Annals of Internal Medicine* editorial addressed GH-secretagogue use for aging directly, calling it 'not yet ready for prime time' — and that assessment has not been updated by subsequent trial data [9]. Community marketing sometimes cites the pediatric growth-velocity data or the GHRH-analog cognition trial as evidence for wellness use in healthy adults; that is an extrapolation the published literature does not support.

---

An independent literature digest on GHRH-analog research peptides — citations, not prescriptions.